-
公开(公告)号：US20210205420A1
公开(公告)日：2021-07-08
申请号：US16997781
申请日：2020-08-19
发明人： Randall J. Mrsny , Tahir Mahmood
IPC分类号： A61K38/45 , C07K14/54 , A61K38/16 , A61K38/20 , A61K38/26 , A61K38/48 , A61K38/49 , A61K38/50 , A61K38/51 , A61K38/27 , A61K38/17 , C07K16/24
摘要： The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.
-
公开(公告)号：US20210171597A1
公开(公告)日：2021-06-10
申请号：US17169396
申请日：2021-02-05
发明人： Randall J. Mrsny , Tahir Mahmood , Amir Porat , Charles Olson , Sally Postlethwaite , Weijun Feng , Khushdeep Mangat
摘要： Described herein are cholix-IL-10 fusion proteins, and methods of use thereof, which can be characterized by a distinct response in an individual when administered. This distinct response can comprise changes in levels of one or more markers in the individual and/or co-localization of IL-10 in the Lamina propria of the individual. Further described herein, in some embodiments, are oral formulations of the cholix-IL-10 fusion proteins. Described herein are methods for the purification of an IL-10 delivery construct, including methods for refolding and enrichment, which can result in maintenance of a high percentage of the IL-10 delivery constructs in the biologically active dimer form. Described herein are oral formulations configured for site-specific release of a therapeutic protein in the small intestines or colon. In some cases, the therapeutic protein is in the form of a dimer, such as an IL-10 delivery construct capable of crossing the gut epithelium.
-
公开(公告)号：US11027020B2
公开(公告)日：2021-06-08
申请号：US16902256
申请日：2020-06-15
摘要： The present disclosure provides non-naturally occurring fusion molecules comprising therapeutic cargo moieties, such as IL-22 with a carrier. The disclosure also provides methods and compositions for the production, purification, refolding, formulation, and administration of fusion molecules. Methods and for using the purified molecules to treat and prevent diseases or disorders are also provided herein.
-
公开(公告)号：US10799565B2
公开(公告)日：2020-10-13
申请号：US16151533
申请日：2018-10-04
发明人： Randall J. Mrsny , Tahir Mahmood
IPC分类号： A61K38/20 , A61K38/45 , A61K39/395 , C07K16/24 , C07K14/54 , A61K38/16 , A61K38/26 , A61K38/48 , A61K38/49 , A61K38/50 , A61K38/51 , A61K38/27 , A61K38/17
摘要： The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders. The present disclosure relates to a non-toxic mutant form of the Vibrio cholera Cholix gene (ntCholix), a variant of Cholix truncated at amino acid A386 (Cholix386) and the use of other various Cholix-derived polypeptide sequences to enhance intestinal delivery of biologically-active therapeutics. The systems and methods described herein provide for: the ability to deliver macromolecule doses without injections; the ability to deliver cargo such as siRNA or antisense molecules into intracellular compartments where their activity is required; and the delivery of nanoparticles and dendrimer-based carriers across biological membranes.
-
公开(公告)号：US20200306383A1
公开(公告)日：2020-10-01
申请号：US16902256
申请日：2020-06-15
发明人： Amir Porat , Randall J. Mrsny , Elbert Seto , Tahir Mahmood , Charles Olson , Weijun Feng
摘要： The present disclosure provides non-naturally occurring fusion molecules comprising therapeutic cargo moieties, such as IL-22 with a carrier. The disclosure also provides methods and compositions for the production, purification, refolding, formulation, and administration of fusion molecules. Methods and for using the purified molecules to treat and prevent diseases or disorders are also provided herein.
-
公开(公告)号：US10786556B2
公开(公告)日：2020-09-29
申请号：US16220923
申请日：2018-12-14
发明人： Randall J. Mrsny , Tahir Mahmood
IPC分类号： A61K38/45 , C07K14/54 , A61K38/16 , A61K38/20 , A61K38/26 , A61K38/48 , A61K38/49 , A61K38/50 , A61K38/51 , A61K38/27 , A61K38/17 , C07K16/24
摘要： The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.
-
公开(公告)号：US20190117742A1
公开(公告)日：2019-04-25
申请号：US16207611
申请日：2018-12-03
发明人： Randall J. Mrsny , Tahir Mahmood
IPC分类号： A61K38/45 , A61K38/27 , A61K38/51 , A61K38/50 , A61K38/49 , A61K38/48 , A61K38/26 , A61K38/20 , A61K38/16 , C07K14/54 , C07K16/24 , A61K38/17
摘要： The present disclosure relates to pharmaceutical compositions comprising a non-naturally occurring fusion molecule and one or more pharmaceutically acceptable carriers, formulated for oral delivery to a subject, and designed to provide for improved, effective therapies for treatment of, e.g., inflammatory diseases, autoimmune diseases, cancer, metabolic disorders, and growth deficiency disorders.
-
-
-
-
-
-
搜索结果
37 条记录 (耗时 0.024 秒)
